Screener
Supernus Pharmaceuticals SUPN Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(2,293) | $(11,827) |
| Other comprehensive gain (loss) | ||
| Unrealized gain (loss) on marketable securities, net of tax | (211) | 30 |
| Other comprehensive gain (loss) | (211) | 30 |
| Comprehensive loss | $(2,504) | $(11,797) |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- Supernus Pharmaceuticals (SUPN) reported comprehensive income (loss), net of tax, attributable to parent of -$2.5M in Q1 2026.
Ask your AI about Supernus Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude